{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:52:01Z","timestamp":1773013921138,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clgc.2019.09.006","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T01:58:43Z","timestamp":1569549523000},"page":"e103-e111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Kazutaka","family":"Okita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-4079","authenticated-orcid":false,"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadafumi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senji","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Ishidoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Mitsuzuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.09.006_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/iju.13380","article-title":"Evidenced-based clinical practice guideline for prostate cancer","volume":"24","author":"Kakehi","year":"2017","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/iju.13593","article-title":"Epidemiology of prostate cancer in Asian countries","volume":"25","author":"Kimura","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/iju.13512","article-title":"Current treatment strategies for advanced prostate cancer","volume":"25","author":"Komura","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s10147-016-1049-y","article-title":"Recent progress and perspectives on prostate cancer biomarkers","volume":"22","author":"Hatakeyama","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/iju.13473","article-title":"Metabolic changes in patients with prostate cancer during androgen deprivation therapy","volume":"25","author":"Mitsuzuka","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00345-018-2590-2","article-title":"Impact of nutritional status on the prognosis of patients with metastatic hormone-naive prostate cancer: a multicenter retrospective cohort study in Japan","volume":"37","author":"Okamoto","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/iju.13870","article-title":"Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer","volume":"26","author":"Shiota","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib8","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s00345-019-02664-3","article-title":"Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Hamano","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","article-title":"Clinical and molecular features of treatment-related neuroendocrine prostate cancer","volume":"25","author":"Akamatsu","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/iju.13556","volume":"25","author":"Nakajima","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/iju.13535","article-title":"Local treatment for metastatic prostate cancer: a systematic review","volume":"25","author":"Tilki","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/iju.14009","article-title":"Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: long-term outcomes","volume":"26","author":"Tanaka","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s10147-017-1230-y","article-title":"No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer","volume":"23","author":"Miyake","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10147-019-01413-1","article-title":"Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study","volume":"24","author":"Iguchi","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"7 Suppl","key":"10.1016\/j.clgc.2019.09.006_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2019.37.7_suppl.256","article-title":"Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: a retrospective study of greater than 2500 patients","volume":"37","author":"Higano","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s10147-018-01388-5","article-title":"Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain\u00a0clinical benefit from early docetaxel administration","volume":"24","author":"Shigeta","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.006_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.006_bib19","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1016\/j.clgc.2017.07.016","volume":"15","author":"Matsubara","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.006_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clgc.2016.06.010","article-title":"Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan","volume":"15","author":"Miyake","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.006_bib21","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/pros.23373","article-title":"Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer","volume":"77","author":"Mori","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2019.09.006_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2017.06.004","volume":"16","author":"Oh","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.006_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clgc.2017.09.008","article-title":"Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.006_bib24","doi-asserted-by":"crossref","first-page":"500.e1","DOI":"10.1016\/j.urolonc.2018.08.002","volume":"36","author":"Oh","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.euo.2018.10.011","article-title":"Development and validation of a novel prognostic model for predicting overall survival in treatment-naive castration-sensitive metastatic prostate cancer","volume":"2","author":"Akamatsu","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib26","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1038\/s41598-019-48600-8","article-title":"Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer","volume":"9","author":"Narita","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2019.09.006_bib27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/jjco\/hyy060","article-title":"Two years of bicalutamide monotherapy in patients with biochemical relapse after radical prostatectomy","volume":"48","author":"Okubo","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12032-017-1050-y","article-title":"Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis","volume":"34","author":"Matsumoto","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-016-0859-0","article-title":"The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis","volume":"34","author":"Narita","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.006_bib31","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib32","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"7 Suppl","key":"10.1016\/j.clgc.2019.09.006_bib33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2019.37.7_suppl.264","article-title":"Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study","volume":"37","author":"Lozano","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib34","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1016\/j.clgc.2019.07.001","article-title":"New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes","volume":"17","author":"Di Nunno","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.006_bib35","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S1470-2045(18)30456-X","article-title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Saad","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.006_bib37","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/j.clgc.2016.12.029","article-title":"18F-PSMA-1007 PET\/CT detects micrometastases in a patient with biochemically recurrent prostate cancer","volume":"15","author":"Giesel","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.006_bib38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/iju.14012","article-title":"How does (68) Ga-prostate-specific membrane antigen positron emission tomography\/computed tomography impact the management of patients with prostate cancer recurrence after surgery?","volume":"26","author":"Bianchi","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.006_bib39","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.09.006_bib40","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1038\/s41598-019-40719-y","article-title":"Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer","volume":"9","author":"Sumiyoshi","year":"2019","journal-title":"Sci Rep"},{"issue":"15 Suppl","key":"10.1016\/j.clgc.2019.09.006_bib41","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2017.35.15_suppl.5002","article-title":"A\u00a0randomized phase II cross-over study of abiraterone\u00a0+ prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Chi","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:21Z","timestamp":1761564741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319302757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1558767319302757"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}